1. Home
  2. HAYW vs LIVN Comparison

HAYW vs LIVN Comparison

Compare HAYW & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HAYW

Hayward Holdings Inc.

HOLD

Current Price

$17.00

Market Cap

3.5B

Sector

Technology

ML Signal

HOLD

Logo LivaNova PLC

LIVN

LivaNova PLC

HOLD

Current Price

$67.34

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAYW
LIVN
Founded
1925
1987
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.5B
IPO Year
2021
1993

Fundamental Metrics

Financial Performance
Metric
HAYW
LIVN
Price
$17.00
$67.34
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$18.00
$67.38
AVG Volume (30 Days)
1.7M
619.7K
Earning Date
02-25-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
44.13
N/A
EPS
0.62
N/A
Revenue
$1,099,855,000.00
$1,348,962,000.00
Revenue This Year
$7.17
$12.25
Revenue Next Year
$5.24
$6.68
P/E Ratio
$26.82
N/A
Revenue Growth
9.66
8.63
52 Week Low
$11.10
$32.48
52 Week High
$17.73
$67.92

Technical Indicators

Market Signals
Indicator
HAYW
LIVN
Relative Strength Index (RSI) 60.79 62.34
Support Level $15.36 $64.23
Resistance Level $16.36 $67.20
Average True Range (ATR) 0.44 1.90
MACD 0.04 0.15
Stochastic Oscillator 97.05 82.36

Price Performance

Historical Comparison
HAYW
LIVN

About HAYW Hayward Holdings Inc.

Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2024.

About LIVN LivaNova PLC

UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Share on Social Networks: